Avid Bioservices Inc (CDMO)

[hutschi]

Gladiator Bio...

GLAdiator Biosciences is advancing a proprietary targeting and internalization technology recently spun out of Bayer
Healthcare. This platform exploits the ability of the gamma-carboxyglutamic-acid domain (GLA) to recognize and target
phoshatidylserine. Relative to normal cells, phosphatidylserine expression is increased on cancer cells, infected cells, stem
cells, and exosomes. Pre-clinical studies performed in collaboration with Stanford University and University of Georgia
validate that GLA recognizess and internalizes into target cells. The GLAdiator platform offers the potential to precisely
target delivery of common (small molecules, biologics) and unique (e.g. nucleotides, stapled peptides, gene editing
machinery) molecules for a broad range of diagnostic and therapeutic applications. Formed in late 2017, GLAdiator is
raising funds to support the validation of a clinical lead candidate.

https://lifesciencenationnewsletter.files.wordpress.com/2018/01/resi-jpm-program-guide-1-3-2018-digital_100-compressed.pdf?bcsi_scan_1014b4c4c7c5e188=0&bcsi_scan_filename=resi-jpm-program-guide-1-3-2018-digital_100-compressed.pdf